Celcuity got its cancer drug approved. Then its stock dipped

July 17, 2026 02:03 PM EDT PharmaFDA+ Cel­cu­ity got its can­cer drug ap­proved. Then its stock dipped Nicole DeFeudis Senior Reporter The FDA’s ap­proval for Cel­cu­ity’s can­cer drug Revtor­pyk on Tues­day was wide­ly an­tic­i­pat­ed. What Wall Street didn’t ex­pect was that the drug … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER